Kus Kylee J B, Murad Fadi, Smile Timothy D, Chang Michael, Ashrafzadeh Sepideh, Zhou Guohai, Ilori Evelyn O, Koyfman Shlomo A, Vidimos Allison T, Schmults Chrysalyne D, Ruiz Emily S
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Oakland University William Beaumont School of Medicine, Rochester, Michigan.
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
J Am Acad Dermatol. 2022 Apr;86(4):766-773. doi: 10.1016/j.jaad.2021.11.002. Epub 2021 Nov 11.
Lymphovascular invasion (LVI) is an aggressive histologic finding but is excluded from current staging systems due to its lack of demonstrated independent prognostic significance.
To evaluate the impact of LVI on cutaneous squamous cell carcinoma tumor outcomes.
In total, 10,707 cutaneous squamous cell carcinoma tumors from a 20-year, retrospective, multicenter cohort were stratified by the presence (LVI) or absence (LVI) of LVI. Outcomes (local recurrence, in-transit metastasis, nodal metastasis, disease-specific death) were compared based on low (Brigham and Women's Hospital [BWH] stage T1/T2a) and high (BWH T2b/T3) tumor stages.
Of the 10,707 tumors, 78 had LVI. The analysis of low-stage BWH tumors showed the LVI group had a significantly higher 5-year cumulative incidence of local recurrence (LVI: 12.3%; LVI: 1.1%; P < .01), metastasis (LVI: 4.2%; LVI: 0.4%; P < .01), and disease-specific death (LVI: 16.2%; LVI: 0.4%; P < .01). The analysis of BWH high-stage tumors showed the LVI group maintained a higher 5-year cumulative incidence of metastasis (LVI: 28.5%; LVI: 16.8%; P = .06) and disease-specific death (LVI: 25.3%; LVI: 13.9%; P = .03), however, there was no difference in local recurrence (LVI: 16.3%; LVI: 15.8%; P = .11).
Retrospective study design.
LVI cutaneous squamous cell carcinomas have higher rates of metastasis and death at 5 years. Future staging systems should consider incorporating LVI.
淋巴管浸润(LVI)是一种侵袭性的组织学表现,但由于其缺乏已证实的独立预后意义,目前的分期系统将其排除在外。
评估LVI对皮肤鳞状细胞癌肿瘤预后的影响。
对一个为期20年的回顾性多中心队列中的10707例皮肤鳞状细胞癌肿瘤,根据是否存在LVI进行分层。基于低(布莱根妇女医院[BWH] T1/T2a期)和高(BWH T2b/T3期)肿瘤分期比较预后(局部复发、途中转移、淋巴结转移、疾病特异性死亡)。
在10707例肿瘤中,78例有LVI。对低分期BWH肿瘤的分析显示,LVI组局部复发的5年累积发生率显著更高(LVI:12.3%;无LVI:1.1%;P <.01)、转移(LVI:4.2%;无LVI:0.4%;P <.01)和疾病特异性死亡(LVI:16.2%;无LVI:0.4%;P <.01)。对BWH高分期肿瘤的分析显示,LVI组转移的5年累积发生率更高(LVI:28.5%;无LVI:16.8%;P = 0.06)和疾病特异性死亡(LVI:25.3%;无LVI:13.9%;P = 0.03),然而,局部复发无差异(LVI:16.3%;无LVI:15.8%;P = 0.11)。
回顾性研究设计。
有LVI的皮肤鳞状细胞癌5年时转移和死亡发生率更高。未来的分期系统应考虑纳入LVI。